Please assess the completion status of the following clinical trial:

Trial Title: The Efficacy of Xuebijing Injection on Sepsis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~Patients will be eligible for inclusion if all of the inclusion criteria are met~1. Sepsis-3 criteria from Society of Critical Care Medicine (SCCM) /European Society of Intensive Care Medicine (ESICM)~2. 18≤ age ≤75years~3. 2 ≤SOFA ≤13~4. obtain informed consent~Exclusion Criteria:~1. Diagnosis of sepsis for more than 48 h;~2. Pregnant and lactating women;~3. Severe primary disease including unrespectable tumours, blood diseases and Human Immunodeficiency Virus (HIV);~4. Severe liver and kidney dysfunction (single liver or kidney SOFA score ≥ 3 points);~5. Use of an immunosuppressant or having an organ transplant within the previous 6 months;~6. Participating in other clinical trials in the previous 30 days.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Intervention Group (Type: EXPERIMENTAL): 100ml Xuebijing Injection will be dissolved in 100 mL of normal saline every 12 hours for 5 days in blind fashion.
- Placebo group (Type: PLACEBO_COMPARATOR): normal saline 200 mL every 12 hours for 5 days

Based on this trial design, predict the completion outcome and termination type (if applicable).